Item 8.01. Other Events.

On November 17, 2020, Brainstorm Cell Therapeutics Inc. (the "Company") issued a press release announcing Topline Results from its NurOwn® Phase 3 ALS Study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company will host a conference call and live webcast at 8:30 am ET on Tuesday, November 17, 2020 to discuss the Topline Results from its NurOwn® Phase 3 ALS Study. A live webcast of the conference call may be accessed by visiting the Investors & Media section of the Company's website at http://www.ir.brainstorm-cell.com.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits



Exhibit No.   Description
  99.1          Press Release issued by Brainstorm Cell Therapeutics Inc., dated
              November 17, 2020
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses